Keywords: gilead, falls, chmp, rejects, cf, drug, shares
Gilead falls 2.4% as CHMP rejects CF drug
Article | 30 March 2009
Shares in Gilead Sciences fell 2.4 % to $44.05 in afternoon trading on March 19, after the US drugmaker's cystic fibrosis drug aztreonam lysine ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
